NasdaqCM - Nasdaq Real Time Price • USD
TG Therapeutics, Inc. (TGTX)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 6:47 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -0.04 | -0.07 | -0.11 | 0.53 |
| Low Estimate | -0.12 | -0.15 | -0.51 | -0.1 |
| High Estimate | 0.05 | -0.01 | 0.18 | 0.93 |
| Year Ago EPS | -0.28 | -0.34 | 0.09 | -0.11 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 54.58M | 56.56M | 263.85M | 424.3M |
| Low Estimate | 46M | 52.11M | 239.76M | 326.92M |
| High Estimate | 59M | 59.4M | 325.28M | 540.3M |
| Year Ago Sales | 7.8M | 17.45M | 233.66M | 263.85M |
| Sales Growth (year/est) | 599.50% | 224.10% | 12.90% | 60.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.37 | -0.25 | 0.12 | -0.1 |
| EPS Actual | -0.28 | -0.34 | 0.73 | -0.1 |
| Difference | 0.09 | -0.09 | 0.61 | 0 |
| Surprise % | 24.30% | -36.00% | 508.30% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.04 | -0.07 | -0.11 | 0.53 |
| 7 Days Ago | -0.04 | -0.07 | -0.11 | 0.48 |
| 30 Days Ago | -0.04 | -0.07 | -0.11 | 0.48 |
| 60 Days Ago | -0.1 | -0.07 | -0.13 | 0.53 |
| 90 Days Ago | -0.11 | -0.06 | -0.11 | 0.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TGTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 85.70% | -- | -- | 0.40% |
| Next Qtr. | 79.40% | -- | -- | 9.90% |
| Current Year | -222.20% | -- | -- | 4.30% |
| Next Year | 581.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/18/2024 |
| Reiterates | JP Morgan: Overweight to Overweight | 4/18/2024 |
| Reiterates | Ladenburg Thalmann: Buy to Buy | 4/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 2/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
Related Tickers
AXSM Axsome Therapeutics, Inc.
73.08
+2.78%
IOVA Iovance Biotherapeutics, Inc.
11.86
+4.77%
MDGL Madrigal Pharmaceuticals, Inc.
218.38
+2.29%
OCUL Ocular Therapeutix, Inc.
5.0000
-1.48%
ALT Altimmune, Inc.
7.57
+1.34%
ARDX Ardelyx, Inc.
6.39
-1.84%
AUPH Aurinia Pharmaceuticals Inc.
5.09
+0.79%
VKTX Viking Therapeutics, Inc.
64.93
+1.69%
DAWN Day One Biopharmaceuticals, Inc.
16.64
+8.19%
IBRX ImmunityBio, Inc.
5.49
+11.13%